Windlas Biotech Ashok Kumar Windlass resigns
Windlas Biotech (BSE: WINDLAS) said Ashok Kumar Windlass has resigned. The company is valued at about ₹1,815 crore.
What happened
Windlas Biotech (BSE: WINDLAS) informed the stock exchanges on 5 November 2026 at 05:18 PM that Ashok Kumar Windlass has resigned.
Company snapshot
Windlas Biotech is a small-cap company, with a market value of about ₹1,815 crore.
The stock last traded at ₹879.6, against a 52-week range of ₹697.4–₹1,181.9 (25.6% below the high).
Before this filing the shares had moved −18.7% over the month and +2.0% over three months. Average daily turnover over the last 20 sessions was about ₹6.9 crore.
Promoters held 63.31% at the end of Q1 FY27. Foreign institutions owned 2.04% and domestic institutions 9.84%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 210 | 17.7 | 8.43 |
| Q2 FY26 | 222 | 17.8 | 8.48 |
| Q3 FY26 | 233 | 15 | 7.12 |
| Q4 FY26 | 238 | 16 | 7.58 |
| Q1 FY27 | 248 | 17.7 | 8.46 |
What history shows
This is not the company's first management change disclosure: BCEIE has 3 earlier filings of this kind on record since May 2026.
After those filings, the stock fell 2.7% on average the next trading day (3 filings with price data).
Market-wide, 4,282 management change filings with an impact score of 50 or more saw an average next-day move of −0.1%, with 44% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 13 Oct 2026 | Resignation of Mr. Vivek Dhariwal (DIN: 02826679), Independent… | −1.3% | — |
| 12 Oct 2026 | Intimation of change in the composition of the Board in terms of… | −3.4% | — |
| 12 Oct 2026 | Appointment and Resignation of Directors | −3.4% | — |
What to watch
- The appointment of a successor and any change in strategy or guidance.
- 5 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.